Portal de Periódicos da CAPES

Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion

1974; Wiley; Volume: 15; Issue: 6 Linguagem: Inglês

10.1002/cpt1974156551

1532-6535

Gottfried Härtel, Antti Louhija, Aarne Konttinen,

Cardiac Arrhythmias and Treatments

The effect of a new antidysrhythmic drug, disopyramide, was tested in a double‐blind clinical trial in 52 patients undergoing electroconversion of atrial fibrillation. During a 3 month follow‐up, the number of patients remaining in sinus rhythm after successful electroconversion was higher (p < 0.05) in the disopyramide group (72%) than in the placebo group (30%).